Biotech | January 04, 2022
Yokogawa invests in glycan production company GlyTech
Partnering to build biosynthesis processes and a pharmaceutical production platform
Partnering to build biosynthesis processes and a pharmaceutical production platform
ASC10 is an oral direct-acting antiviral drug candidate targeting RNA dependent RNA polymerase (RdRp) to treat SARS-CoV-2 infection
The contract award from the U.S. Department of Defense (DoD), on behalf of the U.S. Department of Health and Human Services, is part of an effort to ensure secure local supply and production capacity for critical products for pandemic preparedness
Serum has a capacity of 250-275 million whereas Bharat Biotech has a capacity of 50-60 million
ZyCoV-D is the first DNA plasmid vaccine in the world for human use, developed indigenously by the company against the Covid-19 virus
New Gibco AAV-MAX Helper Free AAV Production System helps reduce production costs and streamline the transition from research to clinical environments
CDSCO to fast-track trials and approval for COVID19 vaccine
The first six batches are being shipped to the Gamaleya Center, Moscow for the quality approval
The company is confident of commencing production at both Mahad and Chiplun units soon
The Cephalosporin Injectables plant has a total capacity of 26.4 million vials per year while Ethiopia is having a demand for 16 million vials
Subscribe To Our Newsletter & Stay Updated
